Nexalin Technology, Inc.

Item Submission 5.07 of Maters to a Vote of Security Holders. The annual meeting (the “Annual Meeting”) of the stockholders of Nexalin Technology, Inc. (the “Company”) was convened at 10:00 a.m. Eastern time on August 11, 2026. Of the 22,011,302 shares of the Company’s common stock, par value $0.001 per share (the “common stock”), outstanding at the close of business on July 6, 2026, the record date for the Annual Meeting, 13,912,110 shares of common stock were present or represented by proxy at the Annual Meeting, which amounts to approximately 63.2% of the shares of the Company’s common stock outstanding and entitled to vote. As a result, quorum was met. At the Annual Meeting, the Company’s stockholders voted on the six proposals described below. The results of the items voted on at the Annual Meeting are as follows. Item One: Election of five directors of the Company: Name For Withheld Broker Non-Votes ─────────────────────────────────────────────────────────── Leslie 8,705,295 432,207 4,774,608 Bernhard Mark 8,840,686 296,816 4,774,608 White David 8,785,477 352,025 4,774,608 Owens, M.D. Alan 8,790,402 347,100 4,774,608 Kazden Ben 8,763,598 373,904 4,774,608 V. Hu, M.D. Item Two: Approval of the Company’s 2026 Equity Incentive Plan: For Against Abstain Broker Non-Votes ────────────────────────────────────────────────────── 8,248,630 815,467 73,405 4,774,608 Item Three: Approval of one or more amendments of the Company’s Second Amended and Restated Certificate of Incorporation to effect one or more reverse stock splits of the Company’s Common Stock, at a ratio ranging from any whole number between and including 1-for-2 and 1-for-100 and in the aggregate not more than 1-for-250, inclusive, as determined by the Company’s board of directors in its discretion, subject to the authority of the board of directors to abandon such amendments: For Against Abstain ────────────────────────────────────────── 12,458,652 1,401,464 51,994 Item Four: Approval and adoption of an Amendment to the Amended and Restated Certificate of Incorporation of the Company to authorize 10 million shares of preferred stock: For Against Abstain Broker Non-Votes ─────────────────────────────────────────────────────────────── 7,863,517 1,208,690 65,295 4,774,608 Item Five: Approval and adoption of an Amendment to the Amended and Restated Certificate of Incorporation of the Company to provide for Officer Exculpation: For Against Abstain Broker Non-Votes ───────────────────────────────────────────────────────────── 8,239,359 772,759 125,384 4,774,608 Item Six: Ratification of the appointment of CBIZ CPAS P.C. as the Company’s independent registered public accounting firm for the year ending December 31, 2026: For Against Abstain ──────────────────────────────────────── 13,362,297 430,308 119,505 Based on the foregoing votes, the director nominees listed in Item 1 were elected, and Items 2, 3, and 6 were approved. Items 4 and 5 were not approved. No other items were presented for stockholder approval at the Annual Meeting.